11/9
09:50 am
urgn
UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported, And Analysts Assigned A US$39.93 Price Target [Yahoo! Finance]
Medium
Report
UroGen Pharma Ltd. (NASDAQ:URGN) Just Reported, And Analysts Assigned A US$39.93 Price Target [Yahoo! Finance]
11/7
02:31 am
urgn
UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... [Yahoo! Finance]
Low
Report
UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ... [Yahoo! Finance]
11/6
11:24 am
urgn
Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/6
08:00 am
urgn
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025
Medium
Report
UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025
11/5
08:00 am
urgn
UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference
Low
Report
UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference
10/30
08:00 am
urgn
UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024
Medium
Report
UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024
10/28
08:00 am
urgn
ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
Medium
Report
ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
10/19
11:01 am
urgn
Investors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five years [Yahoo! Finance]
Medium
Report
Investors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five years [Yahoo! Finance]
10/16
09:40 am
urgn
UroGen Pharma Ltd. (NASDAQ: URGN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $40.00 price target on the stock.
Medium
Report
UroGen Pharma Ltd. (NASDAQ: URGN) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $40.00 price target on the stock.
10/15
04:46 pm
urgn
UroGen Pharma announces FDA acceptance of new drug application for UGN-102 [Seeking Alpha]
Low
Report
UroGen Pharma announces FDA acceptance of new drug application for UGN-102 [Seeking Alpha]
10/15
04:30 pm
urgn
UroGen Announces FDA Acceptance of its New Drug Application for UGN-102
Low
Report
UroGen Announces FDA Acceptance of its New Drug Application for UGN-102
10/15
08:47 am
urgn
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Low
Report
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
10/15
07:51 am
urgn
UroGen Pharma Ltd. (NASDAQ: URGN) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
Low
Report
UroGen Pharma Ltd. (NASDAQ: URGN) was upgraded by analysts at EF Hutton Acquisition Co. I to a "strong-buy" rating.
10/9
08:12 am
urgn
UroGen Pharma names Chris Degnan as CFO [Seeking Alpha]
Low
Report
UroGen Pharma names Chris Degnan as CFO [Seeking Alpha]
10/9
08:00 am
urgn
UroGen Appoints Chris Degnan as Chief Financial Officer
Medium
Report
UroGen Appoints Chris Degnan as Chief Financial Officer
10/3
08:18 am
urgn
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Low
Report
UroGen Pharma Ltd. (NASDAQ: URGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
10/3
05:01 am
urgn
UroGen begins subject dosing in Phase III bladder cancer drug trial [Yahoo! Finance]
Low
Report
UroGen begins subject dosing in Phase III bladder cancer drug trial [Yahoo! Finance]
10/2
08:00 am
urgn
First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Low
Report
First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
9/23
06:01 am
urgn
UroGen Pharma (URGN): Among the Worst Middle East and Africa Stocks to Buy Now [Yahoo! Finance]
Medium
Report
UroGen Pharma (URGN): Among the Worst Middle East and Africa Stocks to Buy Now [Yahoo! Finance]
9/16
08:00 am
urgn
UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041
Low
Report
UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041
9/5
08:00 am
urgn
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8/29
10:17 am
urgn
UroGen Pharma's JELMYTO And UGN-102: A Strong Buy In The Urological Cancer Sector [Seeking Alpha]
Low
Report
UroGen Pharma's JELMYTO And UGN-102: A Strong Buy In The Urological Cancer Sector [Seeking Alpha]
8/29
08:00 am
urgn
UroGen Pharma to Present at Upcoming Investor Conferences
Low
Report
UroGen Pharma to Present at Upcoming Investor Conferences
8/28
01:18 pm
urgn
UroGen Pharma: There Is Some Potential Here [Seeking Alpha]
Low
Report
UroGen Pharma: There Is Some Potential Here [Seeking Alpha]